ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive Non-Hodgkin’s Lymphoma (NHL), as of May 31, 2022 data-cut date
80% ORR and CR rate at dose levels 2 and 3 combined
100% ORR and CR rate in three anti-CD19 CAR-T relapsed patients
50% of evaluable patients with at least six months follow-up remain cancer free
Dose-related increase of ADI-001 exposure observed in blood
Company expects to identify recommended Phase 2 dose in second half of 2022 and initiate at least one potentially pivotal study in first half of 2023
https://finance.yahoo.com/news/adicet-bio-reports-emerging-data-110000994.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.